Patents by Inventor Kevin Czaplinski

Kevin Czaplinski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTI-OLIGOMER IN SITU HYBRIDIZATION PROBES
    Publication number: 20150105298
    Abstract: The disclosure relates to in situ hybridization probes for the detection of target nucleic acid sequences within a sample and methods of making and using the same. The in situ hybridization probes of the current disclosure include a plurality of nucleic acid elements capable of selectively hybridizing to at least a portion of a nucleic acid of interest and/or other nucleic acid elements of the in situ hybridization probe, which enable the detection of a target nucleic acid. The current disclosure also relates to kits which incorporate the in situ hybridization probe compositions of the instant disclosure.
    Type: Application
    Filed: October 10, 2014
    Publication date: April 16, 2015
    Applicant: The Research Foundation for The State University of New York
    Inventor: Kevin Czaplinski
  • Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
    Publication number: 20060134681
    Abstract: The present application provides methods of assaying for compounds that inhibit premature translation termination and nonsense mediated RNA decay in cells.
    Type: Application
    Filed: December 22, 2005
    Publication date: June 22, 2006
    Inventors: Holger Beckmann, Marc Learned, Stuart Peltz, Kevin Czaplinski
  • Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
    Patent number: 7026122
    Abstract: The present application provides methods of assaying for compounds that inhibit premature translation termination and nonsense mediated RNA decay in cells.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: April 11, 2006
    Assignee: PTC Therapeutics, Inc.
    Inventors: Holger Beckmann, Marc Learned, Stuart Peltz, Kevin Czaplinski
  • Subfamily of RNA helicases which are modulators of the fidelity of translation termination and uses thereof
    Patent number: 6989256
    Abstract: An isolated multiprotein complex of S. cerevisiae components is provided that is effective to modulate peptidyl transferase activity during translation. This complex includes a Modulator of Translation Termination protein (Mtt1p, also referred to as helicase B), a Upf1 protein, a peptidyl eukaryotic release factor 1 (eRF1) and a peptidyl eukaryotic release factor 3 (eRF3).
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: January 24, 2006
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Stuart Peltz, Kevin Czaplinski, Jonathan D. Dinman
  • Subfamily of RNA helicases which are modulators of the fidelity of translation termination and uses thereof
    Publication number: 20040115787
    Abstract: This invention provides a method of modulating translation termination efficiency of mRNA and/or promoting degradation of abberant transcripts. Also, this invention provides a method of screening for a drug active involved in enhancing translation termination and a method for identifying a disease state involving defective the protein complex.
    Type: Application
    Filed: August 28, 2003
    Publication date: June 17, 2004
    Inventors: Stuart Peltz, Kevin Czaplinski, Jonathan D. Dinman
  • Subfamily of RNA helicases which are modulators of the fidelity of translation termination and uses thereof
    Patent number: 6630294
    Abstract: This invention provides a method for modulating the efficiency of translation termination of messenger RNA. Also provided are methods of screening for compositions and agents capable of modulating translation termination.
    Type: Grant
    Filed: July 22, 1999
    Date of Patent: October 7, 2003
    Assignee: University of Medicine and Dentistry of New Jersey
    Inventors: Stuart Peltz, Kevin Czaplinski, Jonathan D. Dinman
  • Method of modulating the efficiency of translation termination and degradation of aberrant mRNA involving a surveillance complex comprising human Upf1p,eucaryotic release factor 1 and eucaryotic release factor 3
    Publication number: 20030032158
    Abstract: Provided are novel methods and assays to identify agents and compositions that modulate the ability of the eukaryotic surveillance complex to effect translation termination and degradation of aberrant mRNA.
    Type: Application
    Filed: May 3, 2002
    Publication date: February 13, 2003
    Applicant: University of Medicine and Dentistry of New Jersey
    Inventors: Stuart Peltz, Kevin Czaplinski, Youmin Weng
  • Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
    Publication number: 20030008317
    Abstract: The present application provides methods of assaying for compounds that inhibit premature translation termination and nonsense mediated RNA decay in cells.
    Type: Application
    Filed: August 21, 2002
    Publication date: January 9, 2003
    Applicant: Tularik Inc.
    Inventors: Holger Beckmann, Marc Learned, Stuart Peltz, Kevin Czaplinski
  • METHOD OF MODULATING THE EFFICIENCY OF TRANSLATION TERMINATION AND DEGRADATION OF ABERRANT MRNA INVOLVING A SURVEILLANCE COMPLEX COMPRISING HUMAN UPF1P, EUCARYOTIC RELEASE FACTOR 1 AND EUCARYOTIC RELEASE FACTOR 3
    Patent number: 6486305
    Abstract: This invention provides a method of modulating translation termination efficiency of mRNA and/or promoting degradation of abberant transcripts. Also, this invention provides a method of screening for a drug active involved in enhancing translation termination and a method for identifying a disease state involving defective the protein complex. This invention provides a purified complex comprising an amount of a human Upf1p protein, a peptidyl eucaryotic release factor 1 (eRF1) and a peptidyl eucaryotic release factor 3 (eRF3) effective to modulate translation termination. Further, this invention provides an expression vector which comprises a nucleic acid encoding a human Upf1p protein, a peptidyl eucaryotic release factor 1 (eRF1) and a peptidyl eucaryotic release factor 3 (eRF3) operably linked to a regulatory element.
    Type: Grant
    Filed: August 16, 2000
    Date of Patent: November 26, 2002
    Inventors: Stuart Peltz, Kevin Czaplinski, Youmin Weng
  • Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
    Patent number: 6458538
    Abstract: The present application provides methods of assaying for compounds that inhibit premature translation termination and nonsense mediated RNA decay in cells.
    Type: Grant
    Filed: December 14, 1999
    Date of Patent: October 1, 2002
    Assignees: PTC Therapeutics, Inc., Tularik Incorporated
    Inventors: Holger Beckmann, Marc Learned, Stuart Peltz, Kevin Czaplinski